Detects the JAK2 V617F mutation, which is commonly found in myeloproliferative neoplasms (MPN). DNA is isolated and subjected to allele-specific polymerase chain reaction (PCR) amplification.

Detects JAK2 exons 12 and 13 mutations, which are found a subset of myeloproliferative neoplasms (MPN). DNA sequences of JAK2 exons 12 and 13 are determined using next-generation sequencing technology.

DNA sequencing of the amplified IGH gene variable (V) region is performed and is compared to the germline consensus sequence. The mutation status, V region family, and percent difference from germline are reported.

Quantitative real-time polymerase chain reaction (PCR) is used to detect the t(9;22) BCR-ABL1 fusion transcripts that result in major (p210), minor (p190), or micro (p230) fusion proteins. Minimal residual disease monitoring results for the major breakpoint transcripts are reported and graphed on the International Scale (IS). Monitoring results for the minor and micro breakpoints transcripts are reported.

Detects FLT3 and NPM1 mutations, which are commonly found in acute myeloid leukemia (AML). FLT3 ITD and TKD regions are analyzed by polymerase chain reaction (PCR) and fluorescent fragment size analysis. The signal ratio of the FLT3 ITD region comparing the signal intensity of the mutation to the wild-type is reported in positive cases. Exon 12 of NPM1 is analyzed by PCR to detect small insertion mutations typical of AML.

Detects the FLT3 internal tandem duplication (ITD) and tyrosine kinase domain (TKD) mutations, which are commonly found in acute myeloid leukemia (AML). FLT3 ITD and TKD regions are analyzed by polymerase chain reaction (PCR) and fluorescent fragment size analysis. The signal ratio of the FLT3 ITD region comparing the signal intensity of the mutation to the wild-type is reported in positive cases

Detects mutations in key genes recurrently mutated in chronic lymphocytic leukemia (CLL). DNA sequence of targeted regions of the ATM, BIRC3, NOTCH1, SF3B1, and TP53 genes is determined using next-generation sequencing (NGS) technology.

Detects mutations in key genes recurrently mutated in chronic lymphocytic leukemia (CLL) and related lymphoid neoplasms. DNA sequence of targeted regions of the ASXL1, ATM, BCOR, BIRC3, BRAF, BTK, CCND1, CCND2, CDKN2A, CDKN2B, DDX3X, DNMT3A, FAT1, FBXW7, HIST1H1E, IKZF3, IRAK4, ITPKB, KRAS, MAP2K1, MAP3K14, MAPK1, MED12, MEF2B, MYD88, NFKBIE, NOTCH1, NRAS, PLCG2, PIK3CD, POT1, PTEN, RB1, RIPK1, RPS15, SAMHD1, SETD2, SF3B1, SPEN, SPOP, TET2, TLR2, TP53, TRAF2, TRAF3, UBR5, XPO1 and ZMYM3 genes is determined using next-generation sequencing (NGS) technology.

Detects CALR mutations, which are found in a subset of myeloproliferative neoplasms (MPN). DNA sequence of exon 9 of the CALR gene is determined using amplicon-based, next-generation sequencing (NGS) technology.

Detects clonal B-cell immunoglobulin heavy chain (IGH) gene rearrangement by polymerase chain reaction (PCR) of variable and joining regions on chromosome 14.